Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imiquimod for Actinic Cheilitis
NCT04219358Phase 1Terminated
- Sponsor
- Hospital de Clínicas de Porto Alegre
- Start
- Mar 2019
- Primary completion
- Jun 2020
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of imiquimod in actinic cheilitis (AC) (4 arms), sponsored by Hospital de Clínicas de Porto Alegre. Primary endpoint: Clinical Response. Started Mar 2019; status: terminated.
02
Drugs
imiquimod
03
Conditions
actinic cheilitis (AC)
Beyond the preview
Go deeper on NCT04219358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04219358.